Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEASURER pharmacokinetics study in cirrhosis
NL-OMON58294Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of carvedilol, spironolactone and metformin in Cirrhosis and chronic liver disease (CLD) (3 cohorts), sponsored by Erasmus MC. Primary endpoint: Pharmacokinetic parameters of carvedilol, spironolactone and metformin. Started Feb 2026; status: recruiting.
02
Drugs
carvedilolspironolactonemetformin
03
Conditions
Cirrhosischronic liver disease (CLD)
Beyond the preview
Go deeper on NL-OMON58294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58294.